Public Profile

Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative gene and cell therapies for rare genetic diseases. Founded in 2013, Abeona has made significant strides in the industry, particularly in the fields of gene therapy and regenerative medicine, with a commitment to addressing unmet medical needs. The company’s core products include its proprietary AAV-based gene therapies, which are designed to treat conditions such as Sanfilippo syndrome and other lysosomal storage disorders. Abeona's unique approach leverages advanced technologies to deliver targeted treatments, setting it apart in a competitive market. With a strong pipeline and strategic partnerships, Abeona Therapeutics is well-positioned as a leader in the gene therapy landscape, continually striving to improve patient outcomes and advance the field of genetic medicine.

DitchCarbon Score

How does Abeona Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Abeona Therapeutics Inc.'s score of 18 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.

22%

Let us know if this data was useful to you

Abeona Therapeutics Inc.'s reported carbon emissions

Abeona Therapeutics Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific climate commitments outlined. As such, there are no reported figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions. Additionally, the company has not established any formal reduction targets or initiatives related to climate action. In the absence of specific emissions data or commitments, it is unclear how Abeona Therapeutics is addressing climate change within its operations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Abeona Therapeutics Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Abeona Therapeutics Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Abeona Therapeutics Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Baxter

US
Health and social work services (85)
Updated 4 days ago

Camurus

SE
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Jazz Pharmaceuticals (EUSA Pharma USA) Inc.

US
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Kedrion

IT
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Octapharma

CH
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers